An Update on AVD-104 for the Treatment of GA

Rishi P. Singh, MD

Show Description +

Dr. Singh shares the latest data from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 (Aviceda) for geographic atrophy.

Posted: 7/25/2024

Keywords:

retina-meeting-recap

•

Geographic Atrophy (GA)

•

AVD-104

•

Aviceda

•

Clinical Trials

•

SIGLEC

Up Next

Name: An Update on AVD-104 for the Treatment of GA
Uploaded: 2024-07-25T20:13:19+00:00
Description: Dr. Singh shares the latest data from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 (Aviceda) for geographic atrophy.

Gene Therapy for Wet AMD Shows Promise

Charles C. Wykoff, MD, PhD, FASRS, FACS

Using Retinal Imaging to Identify Alzheimer Biomarkers

Sruthi Arepalli, MD

The Effect of Vitrectomy on AMD Progression

Chase Ludwig, MD

Using AI to Track GA Treatment Response

Ursula M. Schmidt-Erfurth, MD

More on Faricimab for DME: Efficacy and Safety

Chirag Jhaveri, MD

96-Week Safety Data Revealed for 8 mg Aflibercept

Christina Y. Weng, MD, MBA

Exploring DME Outcomes Based on Baseline Vision

Diana V. Do, MD

The PDS: Technical Changes and Clinical Experiences

Dante J. Pieramici, MD

Pegcetacoplan in the Trials and the Real-World

David A. Eichenbaum, MD

Back to All Videos

An Update on AVD-104 for the Treatment of GA

Rishi P. Singh, MD

Dr. Singh shares the latest data from part 1 of the phase 2/3 SIGLEC trial assessing AVD-104 (Aviceda) for geographic atrophy.

Posted: 7/25/2024

Keywords:

retina-meeting-recap

•

Geographic Atrophy (GA)

•

AVD-104

•

Aviceda

•

Clinical Trials

•

SIGLEC

Please log in to leave a comment.

Meeting Coverage:

American Society of Retina Specialists Annual Meeting

An Update on AVD-104 for the Treatment of GA

Up Next

An Update on AVD-104 for the Treatment of GA

More From ASRS: 2024 Coverage